The evidence supports the signature only as an exploratory prognostic biomarker; if independently validated, it could potentially help identify patients for closer monitoring or prospective risk-adapted treatment studies, but the record provides no evidence that treatment escalation or alteration improves outcomes.

The reviewed evidence suggests—but does not establish—that epigenetic-targeted therapies could make selected pediatric brain tumors more responsive to immunotherapy by altering low immunogenicity, immune suppression, or effector-cell dysfunction; prospective studies are needed to test efficacy and neurological safety.

The supplied evidence supports a dosimetric association in simulated plans; it suggests, but does not establish, that a DWA configured for an approximately 1 mm spot size and 0.05%–0.5% energy spread could reduce normal-tissue exposure in pediatric proton therapy without compromising target coverage.

The evidence shows dual-antigen binding and in vitro killing across GD2-positive, ROR1-positive, and dual-positive cell lines; it supports—but does not establish—the hypothesis that co-targeting GD2 and ROR1 could broaden tumor coverage and reduce antigen-escape risk in neuroblastoma, potentially through enhanced immune-effector activity.

The cases support SMARCB1/INI1 loss as a diagnostic and molecular feature of an aggressive PTCL-NOS subset; the proposed sensitivity to histone deacetylase inhibitors is an inference from emerging evidence cited in the abstract and was not demonstrated therapeutically in these two patients.

The reported mouse data support cytarabine-associated ferroptosis, replication arrest, redox imbalance, and testicular-niche stress as candidate contributors to gonadotoxicity; it remains an inference that targeting these pathways could preserve fertility without reducing antileukemic efficacy, and this requires intervention studies and human validation.

The record supports that genomic profiling can identify alterations used to guide treatment in some pediatric patients; it is reasonable—but not demonstrated here—to hypothesize that routine profiling at diagnosis could improve treatment selection or outcomes, because specific therapies, definitions of benefit, and comparative outcome data are not provided.

The study provides evidence that laparoscopic nephrectomy can be feasible in highly selected Wilms tumor cases; it remains an inference requiring prospective validation that adding hilar-to-central vessel distance to established selection criteria could improve operative planning or safety.

The evidence supports persistent sensory dysfunction as a potentially actionable survivorship problem; it can be inferred—but was not tested—that early psychophysical screening followed by tailored nutritional or symptom-support interventions might reduce adverse dietary or quality-of-life effects.

The reported case provides evidence that EXIT can preserve placental support while clinicians secure the airway in a fetus with a large obstructing oral mass; it is reasonable but unproven to infer that prenatal identification and individualized multidisciplinary EXIT planning could reduce airway-related harm in similarly selected cases.

The evidence supports an observational association, not an intervention effect; it suggests—but does not establish—that preventing childhood exposure to domestic violence or addressing subsequent depressive symptoms could reduce long-term cancer risk and warrants prospective interventional study.

The record establishes adoption patterns rather than therapeutic benefit; it supports the inference that more conformal photon and proton modalities could reduce radiation-related late effects through improved targeting, but comparative toxicity, survival, quality-of-life, and access outcomes were not evaluated.